Olema Pharmaceuticals (OLMA) Projected to Post Earnings on Wednesday

Olema Pharmaceuticals (NASDAQ:OLMA) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 14th. Analysts expect Olema Pharmaceuticals to post earnings of ($0.52) per share for the quarter.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its earnings results on Tuesday, March 18th. The company reported ($0.51) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.12. On average, analysts expect Olema Pharmaceuticals to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Olema Pharmaceuticals Stock Performance

OLMA stock opened at $4.60 on Wednesday. The company has a market capitalization of $314.46 million, a P/E ratio of -2.10 and a beta of 2.03. Olema Pharmaceuticals has a 52-week low of $2.86 and a 52-week high of $16.62. The business has a 50-day simple moving average of $4.25 and a two-hundred day simple moving average of $6.48.

Analyst Ratings Changes

OLMA has been the topic of a number of recent analyst reports. Oppenheimer reiterated an “outperform” rating and set a $25.00 target price (down from $30.00) on shares of Olema Pharmaceuticals in a research note on Wednesday, March 19th. JPMorgan Chase & Co. decreased their price objective on shares of Olema Pharmaceuticals from $30.00 to $28.00 and set an “overweight” rating for the company in a report on Friday, March 28th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Olema Pharmaceuticals in a research note on Monday, April 28th.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.